NEJM February 2026 Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer

This clinical study evaluates a promising medical advancement for patients with HER2-positive breast cancer who still have signs of the disease following their initial surgery and treatment. Researchers compared the effectiveness of a newer drug, T-DXd, against the long-standing standard of care, T-DM1, to see which better prevented the cancer from returning. The results were striking, showing that patients receiving T-DXd had a significantly higher survival rate without the disease recurring compared to those on the traditional therapy. While the new treatment demonstrated superior protection against relapse, it also introduced specific side effects, most notably gastrointestinal issues and a serious inflammatory lung condition that requires careful clinical monitoring. Ultimately, the study suggests a shift in the standard treatment protocol for high-risk patients, offering a more effective path toward long-term recovery.